Skip to Navigation Skip to Search Skip to Content
Search All Centers

IASLC Molecular Guideline Testing: What’s Changing?

Published on April 12, 2017

With new lung cancer driver mutations being discovered, will molecular testing guidelines cover them also? Meet Dr. Paul Bunn of the University of Colorado.  Dr. Bunn has dedicated his entire career to researching novel therapies for lung cancer patients.  Having recently returned from the 17th Annual IASLC Targeted Therapy Meeting, Dr. Bunn shares his insights into the latest changes in molecular testing guidelines.

Produced by Patient Power and Antidote in association with the Precision Medicine for Me Initiative.

Featuring

You might also like